Encontrados 3 documentos, a visualizar página 1 de 1
Urgent request for pretomanid label expansion to align with WHO guidelines and ...
Kuksa, L; Andrejak, C; Haecker, B; Bothamley, G; Calcagno, A; Cirillo, DM; Duarte, R; Fatima, R; Ferlazzo, G; Guglielmetti, L; Günther, G; Hewison, CPretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies...
Tuberculosis incidence in foreign-born people residing in European countries in...
Vasiliu, A; Köhler, N; Altpeter, E; Ægisdóttir, TR; Amerali, M; de Oñate, WA; Bakos, Á; D'Amato, S; Cirillo, DM; van Crevel, R; Davidaviciene, E"Background European-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening. Aim We aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening. Methods The Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB...
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Co...
van Leth, F; Brinkmann, F; Cirillo, DM; Dheda, K; Duarte, R; Guglielmetti, L; Kuksa, L; Lange, C; Mitnick, C; Skrahina, A; Zaman, K; Bothamley, Gn/a